Drug Profile
Etanercept biosimilar - Reliance Life Sciences
Alternative Names: EtanerRel; R-TPR-018Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rheumatoid arthritis
Most Recent Events
- 30 Nov 2020 Launched for Rheumatoid arthritis in India (SC) before November 2020 (Reliance Life Sciences website, November 2020)
- 01 Sep 2016 Phase-III clinical trials in Rheumatoid arthritis in India (SC) (CTRI/2016/07/007097)